AIP mutation-driven gigantism with pituitary apoplexy and aggressive tumor growth was controlled by multimodal treatment: surgery, octreotide-LAR, radiotherapy, temozolomide, bevacizumab, and pegvisomant. Here, AIP is linked to neoplasm.